10-K: Pharma-Bio Serv Reports Fiscal Year 2024 Results: Revenue Declines Amid Market Challenges

Pharma-Bio Serv's fiscal year 2024 saw a significant revenue decrease due to project declines in key markets, resulting in a net loss.

Summary

• Pharma-Bio Serv, Inc., a technical compliance consulting firm, reported its fiscal year 2024 results, with a net loss of approximately $0.8 million.
• Revenues decreased to approximately $9.5 million, a $7.5 million decrease compared to the previous year.
• The decline in revenue was attributed to decreases in project revenue in the European, Puerto Rico, and United States consulting markets by approximately $3.7 million, $2.3 million, and $1.5 million, respectively.
• Gross profit decreased by 3.3 percentage points, mainly due to the completion of high-margin projects in the European market in fiscal year 2023.
• Selling, general, and administrative expenses decreased by approximately $150 thousand to $3.8 million, despite investments in business development.
• The company's tax grant from PRIDCO expired on October 31, 2024, and a request for extension is pending.
• As of October 31, 2024, the Company had approximately $13.8 million of working capital.
• The Company purchased 12,100 shares of its common stock under the Stock Repurchase Program during the year.
• The Company declared a cash dividend of $0.075 per share of common stock on February 15, 2024.
• Management believes that current working capital, operations, and cash flows are sufficient to fund anticipated expenses and contractual commitments for the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positives, such as decreased administrative expenses and a stock repurchase program, the overall tone is negative due to the significant decline in revenue and profitability, the net loss, and the expiration of the tax grant. The company faces several risks and challenges, and the future outlook is uncertain.

Positives

• Selling, general, and administrative expenses decreased by approximately $150 thousand.
• The Company maintains a stock repurchase program.
• The Company declared a cash dividend of $0.075 per share of common stock on February 15, 2024.
• The Company is investing in a Lead Generation Technology Platform based on artificial intelligence to research and automate business development opportunities and the recruitment and placement of personnel.

Negatives

• The company reported a net loss of approximately $0.8 million for fiscal year 2024.
• Revenues decreased by $7.5 million compared to the previous year.
• Gross profit decreased by 3.3 percentage points.
• The company's tax grant from PRIDCO expired on October 31, 2024, and an extension request is pending, which could lead to increased tax payments.
• The European, Puerto Rico and United States consulting markets had a decline in projects revenue of approximately $3.7, $2.3 and $1.5 million, respectively.

Risks

• The company's business is concentrated in the life science and medical device industries in Puerto Rico, the United States, and Europe, making it vulnerable to changes in those industries or markets.
• The loss of a major client could impair the company's ability to operate profitably.
• Customer procurement and sourcing practices intended to reduce costs could adversely affect margins and profitability.
• The company may be unable to pass on increased labor costs to clients.
• Consolidation in the pharmaceutical industry may reduce the number of existing and potential customers.
• The company may be held liable for the actions of its employees or contractors when on assignment.
• The company's cash could be adversely affected if the financial institutions in which it holds its cash fail.
• Disruptions in the company's information technology systems could adversely affect its business and results of operations.
• Changes in government regulations relating to the pharmaceutical industry may affect the need for the company's services.
• Changes in tax laws in the United States, Puerto Rico, or other jurisdictions where the company does business may adversely impact the willingness of customers to continue or expand their operations.
• The failure of clients to obtain and maintain patents could impair the company's ability to operate profitably.
• If the company is unable to protect its clients' intellectual property, its ability to generate business will be impaired.
• The limited market in the company's common stock may make it difficult for stockholders to sell shares and may subject the stock to significant price swings.

Future Outlook

Management believes that based on the current level of working capital, operations and cash flows from operations, and the collectability of high-quality customer receivables are sufficient to fund anticipated expenses and satisfy other possible long-term contractual commitments for and beyond the next twelve months.

Management Comments

• Management believes that future profitability and liquidity will depend on the local and global economy, including any impacts of regional or global conflicts, price inflation, pandemics, changes in tax laws, worldwide life science manufacturing industry consolidations, operational constraints imposed by customers due to pandemics and resources management trends, and the company's ability to seek service opportunities and adapt to industry trends.

Industry Context

The company operates in the compliance consulting service sector, which includes local compliance and validation consulting firms, United States dedicated validation and compliance consulting firms, and large publicly traded and private domestic and foreign engineering and consulting firms. The industry is highly competitive and fragmented, with competition based on reputation, track record, experience, quality of service, and price.

Comparison to Industry Standards

• It is difficult to compare Pharma-Bio Serv's results directly to industry standards without specific data on comparable companies.
• However, the decline in revenue and profitability suggests that the company is underperforming compared to some of its competitors.
• Larger competitors with greater resources may have an advantage in the current market environment.
• Companies like Jacobs Engineering Group, Tetra Tech, and AECOM offer similar consulting services and have a broader range of capabilities and greater financial stability.
• Smaller, specialized firms may be more agile and able to adapt to changing market conditions, but may lack the resources to compete for larger projects.

Legal Proceedings

• The Companys subsidiaries are pursuing assets and monies from Romark to collect the judgment of $6,717,431.69.

Related Party Transactions

• The Company leases its headquarters facilities in Dorado, Puerto Rico, from an affiliate of our past Chairman of the Board of Directors.
• The Company entered into an agreement with a company (the AI Company) which is an affiliate to one of the members of our Board of Directors, whereas for $250,000 the Company obtained (i) the development of a dashboard tool (the Lead Generation Technology Platform) based on artificial intelligence which will research and automate business development opportunities and the recruitment and placement of personnel for the Company, (ii) a 2.44% membership interest (the Membership Interest) in the AI Company, and (iii) a two year term grant of option (the Option) to obtain an aggregate 16.67% interest in the AI Company at an exercise price of $1,750,000.

Stakeholder Impact

• Shareholders may be concerned about the decline in revenue and profitability and the resulting net loss.
• Employees may be affected by potential cost-cutting measures or restructuring efforts.
• Customers may be impacted by changes in the company's service offerings or pricing.
• Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.

Next Steps

• The company is actively pursuing to expand its services in the United States, European and Brazilian markets as part of its growth strategy.
• The company has requested PRIDCO the renegotiation of the tax grant for an additional term of fifteen years.
• The Companys subsidiaries will continue the collection efforts with Romark.

Key Dates

Keywords

compliance consulting, pharmaceutical, biotechnology, medical devices, regulatory affairs, validation, technology transfer, Puerto Rico, United States, Europe, Brazil